Related Experiment Video

Updated: Jun 4, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma

Christopher Abdullah1, Xiaolei Wang, Dorothea Becker

  • 1Department of Pathology, University of Pittsburgh, PA, USA.

Cell Cycle (Georgetown, Tex.)
|March 2, 2011
PubMed

Insights

Targeting cell cycle progression in advanced melanoma with cyclin-dependent kinase (CDK) inhibitors shows promise. This study found high CDK levels in melanoma and demonstrated that CDK inhibitors reduce melanoma cell proliferation and xenograft growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Melanoma molecular therapy research focuses on identifying therapeutic targets.
  • Cell cycle regulation is crucial for cancer cell proliferation.

Purpose of the Study:

  • To investigate the role of cyclin-dependent kinases (CDKs) in advanced melanoma.
  • To determine if inhibiting CDK function impacts melanoma biological features.

Main Methods:

  • Expression analysis of CDK2, CDK1, and CDK5 in nevi, melanoma in situ, primary, and metastatic melanomas.
  • In vitro studies on melanoma cell lines.
  • Preclinical in vivo studies using human melanoma xenografts.

Main Results:

  • Primary and metastatic melanomas exhibit elevated levels of CDK2, CDK1, and CDK5 compared to nevi and melanoma in situ.
  • A small-molecule CDK inhibitor targeting CDK2, CDK5, CDK1, and CDK9 effectively inhibited melanoma cell proliferation and induced apoptosis in vitro.
  • The CDK inhibitor also impaired the growth of human melanoma xenografts in vivo.

Conclusions:

  • CDK2, CDK1, and CDK5 are highly expressed in advanced melanoma, suggesting their involvement in melanoma progression.
  • Targeting CDKs with specific inhibitors represents a potential therapeutic strategy for advanced melanoma.
  • CDK inhibition demonstrates efficacy in reducing melanoma cell growth and tumor burden.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...